Premenstrual Dysphoric Disorder: Epidemiology and Treatment

Curr Psychiatry Rep. 2015 Nov;17(11):87. doi: 10.1007/s11920-015-0628-3.


Recently designated as a disorder in the DSM-5, premenstrual dysphoric disorder (PMDD) presents an array of avenues for further research. PMDD's profile, characterized by cognitive-affective symptoms during the premenstruum, is unique from that of other affective disorders in its symptoms and cyclicity. Neurosteroids may be a key contributor to PMDD's clinical presentation and etiology, and represent a potential avenue for drug development. This review will present recent literature on potential contributors to PMDD's pathophysiology, including neurosteroids and stress, and explore potential treatment targets.

Keywords: GABA; Menstrual cycle; PMDD; PMS; Premenstrual.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Diagnosis, Differential
  • Diagnostic and Statistical Manual of Mental Disorders
  • Disease Management
  • Female
  • Humans
  • Mood Disorders / diagnosis*
  • Premenstrual Dysphoric Disorder* / diagnosis
  • Premenstrual Dysphoric Disorder* / metabolism
  • Premenstrual Dysphoric Disorder* / psychology
  • Premenstrual Dysphoric Disorder* / therapy
  • Premenstrual Syndrome / diagnosis*
  • gamma-Aminobutyric Acid / metabolism*


  • gamma-Aminobutyric Acid